We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...

Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...

Investment analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Monday, January 27th.

Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...

Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% gain by 2025. Learn more on SRPT stock here.

SAREPTA, La. -- Working smoke detectors get the credit for a woman surviving a fire in her home Monday night. A woman who ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression. Solid Biosciences advances ...

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...